Target intelligence / Profile preview

Regulatory protein RhlR (RhlR) (RhlR)

Target
RhlR
Molecular classification
Transcription factor, LuxR-type regulator, DNA-binding protein, Receptor
01

Overview

Regulatory protein RhlR is a central transcriptional regulator within the complex quorum-sensing (QS) hierarchy of the opportunistic pathogen Pseudomonas aeruginosa (UniProt P54292). It functions as a LuxR-type receptor that is activated upon binding its cognate autoinducer, N-butyryl-L-homoserine lactone (C4-HSL), which is produced by the synthase RhlI (Mukherjee et al., 2017). Once activated, RhlR forms a dimer and binds to specific DNA sequences (lux boxes) to trigger the expression of genes involved in the production of secondary metabolites and virulence factors, such as rhamnolipids, pyocyanin, and elastase (O'Loughlin et al., 2013). These factors are essential for the bacteria's ability to form robust biofilms, evade the host immune system, and cause tissue damage during chronic infections, particularly in patients with cystic fibrosis or compromised immune systems (Eickhoff et al., 2021). Because RhlR controls virulence rather than essential growth processes, it is considered a high-priority target for anti-virulence therapy. Inhibiting RhlR aims to disarm the pathogen and enhance its clearance by the host immune system or conventional antibiotics, potentially reducing the selective pressure that leads to traditional antibiotic resistance (Mukherjee et al., 2017; Eickhoff et al., 2021).

Other names
Quorum-sensing transcriptional regulator RhlRRhlR regulatorTranscription factor RhlR
02

Mechanism of action

Competitive antagonism of the autoinducer binding site or disruption of the RhlR-DNA binding interface to inhibit the transcription of virulence-associated genes.

03

Biological functions

Quorum sensingRegulation of virulence factor productionBiofilm formationGene expression regulationSignal transduction
04

Disease associations

InfectionCystic fibrosis-associated lung infectionChronic wound infectionNosocomial infection
05

Safety considerations

Potential for off-target effects on commensal microbiotaDevelopment of non-lethal resistance mechanismsBioavailability in thick mucus (e.g., in cystic fibrosis)
06

Interacting drugs

mBTL (meta-bromo-thiolactone)

3 more in the full profile.

07

Biomarkers

Rhamnolipid productionPyocyanin levelsElastase B (LasB) activityBiofilm density

Beyond the preview

Go deeper on Regulatory protein RhlR (RhlR) (RhlR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regulatory protein RhlR (RhlR) (RhlR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call